Verrica Pharmaceuticals Inc.

Historical 13F Holders

Symbol
VRCA
CUSIP
92511W108
All holders as of
Q3 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 92511W108 since 12/18/2024, largest first.

Filer % of Class Filed
Caligan Partners LP 13G
10.0% 2/12/2025
Event 12/31/2024
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Armistice Capital, LLC 13G/A
Amended under CUSIP 92511W207 on 11/14/2025
10.0% 8/14/2025
Event 3/31/2025
Perceptive Advisors LLC 13G/A
1.6% 5/15/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q3 2 596 $301.00
2025 Q2 56 24.7 M $13.3 M
2025 Q1 76 29.5 M $13.0 M
2024 Q4 84 30.0 M $21.0 M
2024 Q3 83 14.9 M $21.6 M
2024 Q2 79 18.7 M $137 M
2024 Q1 66 18.0 M $107 M
2023 Q4 71 18.1 M $133 M
2023 Q3 70 15.1 M $58.5 M
2023 Q2 67 14.6 M $84.2 M
2023 Q1 65 12.9 M $84.2 M
2022 Q4 54 10.9 M $29.9 M
2022 Q3 52 10.2 M $29.9 M
2022 Q2 60 11.3 M $21.8 M
2022 Q1 52 8.88 M $72.1 M
2021 Q4 48 12.6 M $115 M
2021 Q3 54 9.17 M $115 M
2021 Q2 55 13.5 M $153 M
2021 Q1 53 13.5 M $205 M
2020 Q4 45 8.96 M $103 M
2020 Q3 48 8.93 M $69.1 M
2020 Q2 49 8.81 M $97.0 M
2020 Q1 50 8.84 M $96.6 M
2019 Q4 54 9.37 M $147 M
2019 Q3 44 9.27 M $137 M
2019 Q2 42 9.02 M $105 M
2019 Q1 41 8.82 M $97.0 M
2018 Q4 43 8.48 M $69.1 M
2018 Q3 47 8.25 M $134 M
2018 Q2 28 8.31 M $164 M